TRVN vs. CANF, VCNX, KTTA, HEPA, ADXS, ASLN, CVKD, TENX, PULM, and CMMB
Should you be buying Trevena stock or one of its competitors? The main competitors of Trevena include Can-Fite BioPharma (CANF), Vaccinex (VCNX), Pasithea Therapeutics (KTTA), Hepion Pharmaceuticals (HEPA), Ayala Pharmaceuticals (ADXS), ASLAN Pharmaceuticals (ASLN), Cadrenal Therapeutics (CVKD), Tenax Therapeutics (TENX), Pulmatrix (PULM), and Chemomab Therapeutics (CMMB). These companies are all part of the "pharmaceutical preparations" industry.
Can-Fite BioPharma (NYSE:CANF) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk, community ranking and media sentiment.
Trevena has a net margin of 0.00% compared to Trevena's net margin of -1,027.46%. Trevena's return on equity of -113.75% beat Can-Fite BioPharma's return on equity.
In the previous week, Can-Fite BioPharma had 1 more articles in the media than Trevena. MarketBeat recorded 1 mentions for Can-Fite BioPharma and 0 mentions for Trevena. Trevena's average media sentiment score of 0.00 equaled Can-Fite BioPharma'saverage media sentiment score.
Can-Fite BioPharma has higher earnings, but lower revenue than Trevena. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.
21.0% of Can-Fite BioPharma shares are owned by institutional investors. Comparatively, 13.6% of Trevena shares are owned by institutional investors. 0.8% of Can-Fite BioPharma shares are owned by company insiders. Comparatively, 2.4% of Trevena shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Can-Fite BioPharma presently has a consensus price target of $15.00, indicating a potential upside of 614.29%. Trevena has a consensus price target of $9.00, indicating a potential upside of 2,019.14%. Given Can-Fite BioPharma's higher possible upside, analysts plainly believe Trevena is more favorable than Can-Fite BioPharma.
Can-Fite BioPharma has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500. Comparatively, Trevena has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500.
Trevena received 614 more outperform votes than Can-Fite BioPharma when rated by MarketBeat users. Likewise, 72.10% of users gave Trevena an outperform vote while only 2.44% of users gave Can-Fite BioPharma an outperform vote.
Summary
Can-Fite BioPharma beats Trevena on 8 of the 15 factors compared between the two stocks.
Get Trevena News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRVN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TRVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
